Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study.
Richeek PradhanOriana H Y YuRobert W PlattLaurent AzoulayPublished in: BMJ open diabetes research & care (2023)
In this large, population-based cohort study, DPP-4 inhibitors were associated with a reduced risk of melanoma but not non-melanoma skin cancer, compared with sulfonylureas.
Keyphrases